ARDSLEY, N.Y.–(BUSINESS WIRE)–September 13, 2018 — Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the…Original Article
Acorda Announces FDA Extends Inbrija NDA Review Period
